Democratic Republic of the Congo

A new study shows the durability of a novel 'disseminating' cytomegalovirus (CMV)-based Ebola virus (Zaire ebolavirus; EBOV) vaccine strategy that may eventually have the potential to reduce ebolavirus infection in wild African ape species.

These are western lowland gorillas, one of the great ape species threatened by Ebola. Credit: Copyright 2012 Chris Whittier

A cytomegalovirus (CMV)-based vaccine provides long-lasting protective immunity against Ebola virus, and has potential for development as a disseminating vaccine strategy to prevent ebolavirus infection of wild African ape populations.

The multi-institutional study is led by Dr Michael Jarvis at Plymouth University, and is published today, 25th March 2015, in Vaccine.

THE ECONOMIST                                                                                                    Jan. 1, 2015
THE first reported case in the Ebola outbreak ravaging west Africa dates back to December 2013, in Guéckédou, a forested area of Guinea near the border with Liberia and Sierra Leone. Travellers took it across the border: by late March, Liberia had reported eight suspected cases and Sierra Leone six. By the end of June 759 people had been infected and 467 people had died from the disease, making this the worst ever Ebola outbreak. The numbers keep climbing. As of December 28th, 20,206 cases and 7,905 deaths had been reported worldwide, the vast majority of them in these same three countries. Many suspect these estimates are badly undercooked.
See complete set of graphs.
http://www.economist.com/blogs/graphicdetail/2015/01/ebola-graphics